PRODUCT INFORMATION



DMXAA

Item No. 14617

CAS Registry No.: 117570-53-3

Formal Name: 5,6-dimethyl-9-oxo-9H-xanthene-4-acetic acid Synonyms: ASA 404, 5,6-Dimethylxanthenone-4-acetic Acid,


NSC 640488, Vadimezan

MF: $C_{17}H_{14}O_4$ 282.3 FW: **Purity:** ≥98%

Supplied as: A crystalline solid

Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

DMXAA is supplied as a crystalline solid. A stock solution may be made by dissolving the DMXAA in the solvent of choice, which should be purged with an inert gas. DMXAA is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of DMXAA in these solvents is approximately 1 and 14 mg/ml, respectively.

DMXAA is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, DMXAA should first be dissolved in DMF and then diluted with the aqueous buffer of choice. DMXAA has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

DMXAA is a xanthene which acts as a tumor vascular disrupting agent, inducing apoptosis in tumor vascular endothelium resulting in necrosis at the tumor core. $^{1.2}$ It potently activates the TANK-binding kinase 1-interferon regulatory factor 3 (TBK1/IRF3) signaling pathway in leukocytes, inducing type-I-interferon (IFN) production.³⁻⁵ Specifically, DMXAA activates the mitochondria- and endoplasmic reticulum-associated protein known as stimulator of interferon genes (STING), leading to TBK1/IRF3 signaling.⁶ DMXAA signals through mouse STING but not human STING. In addition, DMXAA significantly inhibits several kinases in endothelial cells, including the vascular endothelial growth factor (VEGF) receptors VEGFR1 and VEGFR2 (IC₅₀ = 119 and 11 μ M, respectively).⁸

References

- 1. McKeage, M.J. and Baguley, B.C. Cancer 116(8), 1859-1871 (2010).
- 2. Thorpe, P.E. Clin. Cancer Res. 10(2), 415-427 (2004).
- 3. Roberts, Z.J., Goutagny, N., Perera, P.-Y., et al. J. Exp. Med. 204(7), 1559-1569 (2007).
- 4. Tang, C.K., Aoshi, T., Jounai, N., et al. PLoS One 8(3), (2013).
- 5. Wallace, A., LaRosa, D.F., Kapoor, V., et al. Cancer Res. 67(114), 7011-7019 (2007).
- 6. Prantner, D., Perkins, D.J., Lai, W., et al. J. Biol. Chem. 287(47), 39776-39788 (2012).
- 7. Conlon, J., Burdette, D.L., Sharma, S., et al. J. Immunol. 190(10), 5216-5225 (2013).
- 8. Buchanan, C.M., Shih, J.-H., Astin, J.W., et al. Clin. Sci. (Lond) 122(10), 449-457 (2012).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the material can be found on our website.

Copyright Cayman Chemical Company, 09/29/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM